Daily Caffeine Consumption is Associated with Decreased Incidence of Symptoms and Hemodynamic Changes During Pharmacologic Stress with Regadenoson.
Regadenoson is an adenosine A2A receptor agonist widely used as a pharmacologic stress agent for myocardial perfusion imaging (MPI). Approximately 3.4 million regadenoson pharmacologic stress tests were performed annually as of 2011. Caffeine is a competitive antagonist of all adenosine receptor subtypes, thus caffeine is typically withheld 12-24 hours before stress with regadenoson. However, the effects of daily caffeine intake on regadenoson stress are unknown. This study assesses the effects of daily caffeine intake on symptoms and hemodynamic changes during stress testing with regadenoson. Methods: Patients presenting for regadenoson stress MPI were asked their amounts of daily caffeine intake. Chart review was used to collect data on demographics, comorbidities, and use of beta blockers. Data collected from the regadenoson stress test included symptoms, administration of aminophylline, heart rate (HR), blood pressure (BP) and arrhythmias. Chi-squared test and analysis of variance were used to analyze data divided into three categories of caffeine intake (< 200, 200-400, > 400 mg daily). Chi-squared test was used for nominal data and unpaired t-test for continuous data. Results: A total of 101 patients were enrolled with 53% men and 47% women. Of the 101 patients, 89% reported caffeine intake, with 13% reporting heavy caffeine intake (> 400mg daily). Last intake of caffeine was at least 12 hours prior to the test. During the test, 63% of patients reported symptoms, but the test was completed successfully in all patients. Compared to those who do not use caffeine, intake was associated with less chest pain (P = 0.0013), less aminophylline administration (P = 0.0371), lower resting and peak heart rate (P = 0.0497 and 0.0314, respectively) and lower diastolic BP response (P = 0.017) for caffeine users. No associations were found between caffeine intake and arrhythmia or systolic BP response. Conclusion: Caffeine consumers receiving regadenoson stress MPI was very common, and use of regadenoson for MPI in caffeine consumers is safe and associated with lower incidence of certain symptoms compared to non-caffeine consumers. Specifically, caffeine intake was associated with less aminophylline use and chest pain.